Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Capital Planning Advisors LLC

Capital Planning Advisors LLC raised its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 41.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 106,565 shares of the biotechnology company’s stock after buying an additional 31,003 shares during the period. Capital Planning Advisors LLC owned about 0.07% of Heron Therapeutics worth $163,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HRTX. Cutter & CO Brokerage Inc. purchased a new stake in shares of Heron Therapeutics during the 3rd quarter valued at approximately $39,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Heron Therapeutics during the 3rd quarter valued at approximately $39,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Heron Therapeutics during the 2nd quarter valued at approximately $41,000. Sei Investments Co. purchased a new stake in shares of Heron Therapeutics during the 2nd quarter valued at approximately $44,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Heron Therapeutics in the third quarter valued at approximately $45,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

Heron Therapeutics Stock Up 3.6 %

NASDAQ:HRTX opened at $1.69 on Thursday. The company has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.92. The company has a market cap of $256.90 million, a price-to-earnings ratio of -9.38 and a beta of 1.60. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same quarter last year, the firm earned ($0.17) EPS. On average, analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.